Oncologists' Perspective on Dental Care Around the Treatment of Head and Neck Cancer: A Pattern of Practice Survey

2021 ◽  
pp. OP.20.00913
Author(s):  
Matthew C. Ward ◽  
Michael D. Carpenter ◽  
Jenene Noll ◽  
Daniel Carrizosa ◽  
Benjamin J. Moeller ◽  
...  

PURPOSE: Patients with head and neck cancer are at risk of long-term dental complications. Proper dental assessment pre- and post-treatment can improve outcomes but is logistically challenging. We surveyed oncologists to better understand their perspectives surrounding dental care in this unique population. METHODS: We surveyed oncologists at institutions associated with an ongoing national study of oral health after treatment of head and neck cancer. Seventeen questions were used to assess provider characteristics, patterns of practice, patterns of referral, barriers to referral, and willingness to apply fluoride varnish in the oncology clinic. RESULTS: Ninety-seven oncologists were invited from six institutions, of whom 40 (41%) responded. Surgeons represented 45% of the sample, followed by radiation oncologists (40%) and medical oncologists (15%). Both generalists and subspecialists were included. All practiced in a metropolitan area with an academic dental practice, and many felt that this improved access to care. Despite this, most oncologists thought that financial factors were a significant barrier to obtaining timely dental care. Most oncologists performed a dental assessment during visits. Oncologists felt qualified to identify the most significant complications of treatment, such as exposed bone, but felt underqualified to identify early changes in need of intervention. When asked if the oncology clinic could apply fluoride varnish during follow-ups, most stated that this seemed feasible but would require education and financial support. CONCLUSION: Oncologists often perform limited dental evaluations during their routine visits. Given the challenges associated with access to proper dental care for this population, these oncology visits may provide a window for preventative intervention.

2021 ◽  
pp. 238008442110003
Author(s):  
T.M. Nguyen ◽  
U. Tonmukayakul ◽  
H. Calache

The coronavirus disease 2019 (COVID-19) has disrupted essential oral healthcare in Australia. Sources for COVID-19 transmission via dental settings is considered to have high potential due to the production of aerosols and because transmission can occur through the airborne route. However, COVID-19 cases in dentistry is reportedly low. Delayed timely dental care, where severe oral diseases remain undetected, untreated, or asymptomatic such as advanced dental caries, periodontitis, and head and neck cancer, can have detrimental consequences for individuals at increased risk for oral diseases. The dental profession should remain vigilant and advocate for the continuation of essential oral healthcare even in times of uncertainty. Knowledge Transfer Statement: The reportedly low COVID-19 transmission occurring in dental settings highlight achievements made by the dental profession. There are valid reasons to reconsider risk-based essential oral healthcare during the COVID-19 pandemic.


Oral Oncology ◽  
2022 ◽  
Vol 125 ◽  
pp. 105694
Author(s):  
Oded Cohen ◽  
Philip R. Brauer ◽  
Benjamin L. Judson ◽  
Barbara A. Burtness ◽  
Joseph Earles ◽  
...  

Oral Oncology ◽  
2011 ◽  
Vol 47 (7) ◽  
pp. 677-682 ◽  
Author(s):  
Kristine Bjørndal ◽  
Annelise Krogdahl ◽  
Marianne Hamilton Therkildsen ◽  
Jens Overgaard ◽  
Jørgen Johansen ◽  
...  

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17019-e17019
Author(s):  
Samuel Swisher-McClure ◽  
Shayna Cohen ◽  
Justin E. Bekelman ◽  
Jiaqi Li ◽  
Alexander Lin ◽  
...  

1984 ◽  
Vol 98 (8) ◽  
pp. 819-828 ◽  
Author(s):  
Randall P. Morton

SummaryA postal survey of 100 members of the Association of Head and Neck Oncologists of Great Britain was conducted in the first 6 months of 1983. The sample consisted principally of Otolaryngologists (50 per cent), Radiotherapists (14 per cent), Medical Oncologists (10 per cent), Oral Surgeons (10 per cent) and Plastic Surgeons (10 per cent). More than 80 per cent of those who completed the questionnaire used chemotherapy for Head and Neck cancer (72 per cent used it for palliation, and 64 per cent as part of combined modality therapy). There was great variation in the chemotherapeutic regimens used by the various responders. Furthermore, most responders used more than one regimen. Methotrexate was the agent most frequently used. No specific regimen, either single-agent or multiple-agent, enjoyed universal acceptance, although the combination of Vincristine, Bleomycin and Methotrexate was popular. Chemotherapy was thought by most responders to have a useful but as yet undefined place in the management of Head and Neck cancer. This survey underlines the need for prospective, controlled, clinical trials into the efficacy of cytotoxic chemotherapy for Head and Neck cancer.


2019 ◽  
Vol 42 (2) ◽  
pp. 172-178 ◽  
Author(s):  
Eric Adjei Boakye ◽  
Kenton J. Johnston ◽  
Thiago A. Moulin ◽  
Paula M. Buchanan ◽  
Leslie Hinyard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document